Satsuma Pharmaceuticals

OverviewSuggest Edit

Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.

TypePublic
Founded2016
HQSouth San Francisco, CA, US
Websitesatsumarx.com

Latest Updates

Employees (est.) (Jun 2019)11
Job Openings1
Share Price (May 2021)$5.1(-3%)
Cybersecurity ratingAMore

Key People/Management at Satsuma Pharmaceuticals

John Kollins

John Kollins

President & CEO, President & Chief Executive Officer
Ken Takanashi

Ken Takanashi

Board Member
Detlef Albrecht

Detlef Albrecht

Chief Medical Officer
Tom O'Neil

Tom O'Neil

Chief Financial Officer
Rob Janosky

Rob Janosky

Chief Commercial Officer
Robert Schultz

Robert Schultz

Vice President & Head of CMC
Show more

Satsuma Pharmaceuticals Office Locations

Satsuma Pharmaceuticals has offices in South San Francisco and Durham
South San Francisco, CA, US (HQ)
400 Oyster Point Blvd #221South
Durham, NC, US
4819 Emperor Blvd #340
Show all (2)

Satsuma Pharmaceuticals Financials and Metrics

Satsuma Pharmaceuticals Revenue

USD

Net income (FY, 2020)

(47.6m)

EBIT (FY, 2020)

(48.3m)

Market capitalization (7-May-2021)

160.5m

Closing stock price (7-May-2021)

5.1

Cash (31-Dec-2020)

36.3m

EV

127.2m
Satsuma Pharmaceuticals's current market capitalization is $160.5 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

754.0k1.1m4.7m12.1m

R&D expense

4.2m6.4m24.2m36.3m

Operating expense total

4.9m7.5m28.9m48.3m

EBIT

(4.9m)(7.5m)(28.9m)(48.3m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.0m2.5m2.7m

R&D expense

7.4m9.6m8.8m

Operating expense total

8.5m12.2m11.5m

EBIT

(8.5m)(12.2m)(11.5m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

1.7m5.2m22.8m36.3m

Prepaid Expenses

256.0k199.0k7.0m5.6m

Current Assets

1.9m5.4m114.7m73.8m

PP&E

70.0k445.0k832.0k6.5m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

Cash

77.7m22.9m32.1m

Prepaid Expenses

7.6m8.1m7.0m

Current Assets

126.6m108.9m100.7m

PP&E

885.0k1.0m1.3m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(5.2m)(7.3m)(28.2m)(47.6m)

Depreciation and Amortization

10.0k57.0k141.0k239.0k

Accounts Payable

363.0k(177.0k)4.0m(1.6m)

Cash From Operating Activities

(4.3m)(7.0m)(29.6m)(42.3m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020

Net Income

(17.4m)(11.8m)(23.0m)

Depreciation and Amortization

102.0k49.0k106.0k

Accounts Payable

1.4m(809.0k)(1.8m)

Cash From Operating Activities

(22.4m)(13.0m)(23.0m)
USDFY, 2017

Debt/Equity

3 x

Debt/Assets

0.1 x

Financial Leverage

20.7 x
Show all financial metrics

Satsuma Pharmaceuticals Operating Metrics

Aug, 2019

Drugs in Development

37

Patents (Foreign)

9

Patents (US)

6
Show all operating metrics

Satsuma Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Satsuma Pharmaceuticals Online and Social Media Presence

Embed Graph

Satsuma Pharmaceuticals News and Updates

Satsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Announced updated STS101 development plan featuring a new Phase 3 efficacy trial scheduled to begin enrollment mid-2021 with topline results expected in second half of 2022

Satsuma Pharmaceuticals to Present at the 31st Annual Oppenheimer Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on March 16, 2021 at 3:10 …

Satsuma Pharmaceuticals Announces Updated STS101 Development Plan

-New STS101 Phase 3 efficacy trial planned to begin mid-2021 with topline results expected second half of 2022-

Satsuma Pharmaceuticals to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that management will participate in the Evercore ISI 3rd Annual HealthCONx Conference. Please see additional details below:

Satsuma Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today summarized recent business progress  and reported financial results for the second quarter ended June 30, 2020.

Satsuma Pharmaceuticals to To Present at the Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA) a clinical-stage biopharmaceutical company, today announced that John Kollins, President and Chief Executive Officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on…
Show more

Satsuma Pharmaceuticals Blogs

Satsuma Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Business Highlights

-New STS101 Phase 3 efficacy trial (the SUMMIT trial) expected to begin mid-2021 with topline results expected second half of 2022-

Associate Director or Director of Quality Assurance and Compliance

Location RTP North Carolina Satsuma Pharmaceuticals: Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic for the acute treatment of migraine. Our lead drug candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihy…

Satsuma Pharmaceuticals Provides Business Update and Reports Third Quarter 2020 Financial Results

Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021

Satsuma Pharmaceuticals to participate in the following November Virtual Investor Conferences

- Credit Suisse - 29th Annual Healthcare Conference - November 9th -12th

Thomas M. Soloway

Mr. Soloway has been a member of our board of directors since July 2020.  He currently serves as Executive Vice President and Chief Operating Officer of Audentes Therapeutics Inc., an Astellas genetic medicines company committed to developing and commercializing innovative gene therapy products for …
Show more

Satsuma Pharmaceuticals Frequently Asked Questions

  • When was Satsuma Pharmaceuticals founded?

    Satsuma Pharmaceuticals was founded in 2016.

  • Who are Satsuma Pharmaceuticals key executives?

    Satsuma Pharmaceuticals's key executives are John Kollins, Ken Takanashi and Detlef Albrecht.

  • How many employees does Satsuma Pharmaceuticals have?

    Satsuma Pharmaceuticals has 11 employees.

  • Who are Satsuma Pharmaceuticals competitors?

    Competitors of Satsuma Pharmaceuticals include Procaps, Dexa Medica and Infarco.

  • Where is Satsuma Pharmaceuticals headquarters?

    Satsuma Pharmaceuticals headquarters is located at 400 Oyster Point Blvd #221South, South San Francisco.

  • Where are Satsuma Pharmaceuticals offices?

    Satsuma Pharmaceuticals has offices in South San Francisco and Durham.

  • How many offices does Satsuma Pharmaceuticals have?

    Satsuma Pharmaceuticals has 2 offices.